Phase 1/1b Study to Evaluate the Safety & PK of JNJ-73841937 a Third Generation EGFR-TKI as Monotherapy or in Combinations With JNJ-61186372 a Human Bispecific EGFR and cMet Antibody in Participants With Advanced NSCLC

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Non-small Cell Lung Cancer (nsclc)
  • Age: Between 18 years - 100 years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Phase 1 and Phase 1b combination cohorts: Histologically or cytologically confirmed NSCLC with previously identified EGFR mutation. 2) Phase 1 and Phase 1b combination cohorts: Evaluable disease. Phase 1b expansion cohorts: Measurable disease according to RECIST. 3) ECOG performance status grade of 0 or 1. 5.

You may not be eligible for this study if the following are true:

  • 1) Uncontrolled intercurrent illness, including but not limited to poorly controlled hypertension or diabetes, ongoing or active infection (ie, has not discontinued all antibiotics for at least one week prior to first dose of study intervention), or psychiatric illness/social situation that would limit compliance with study requirements. Participants with medical conditions requiring continuous oxygen therapy are excluded. 2) Prior treatment with antiPD-1 or antiPD-L1 antibody within 6 weeks of planned first dose of study intervention. 3) Prior chemotherapy, targeted cancer therapy, immunotherapy (refer to Exclusion Criterion #2 for antiPD-1 or antiPD-L1 therapy), or treatment with an investigational anticancer agent within 2 weeks or 4 half-lives whichever is longer, before the first administration of study intervention(s).

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.